



Supplementary Figure 1: Bland-Altman plots for intra- and interobserver agreement for cardiac measures

A: Intra-observer agreement Bland-Altman plots



B: Inter-observer agreement plots



Supplementary Table 1: Factors associated with enrolment in the study

Variable	Enrolled N=200	Not enrolled N=197	Test coefficient, p-value
Age, y, mean (SD)	10.5 (2.5)	9.9 (2.7)	$t = -2.20$, $p = 0.03$
Sex, n (%) female	96 (48.0)	86 (43.7)	$\text{Chi}^2 = 0.75$, $p = 0.39$
Taking TB treatment, n (%)	1 (0.5)	1 (0.5)	$\text{Chi}^2 = 0.00$, $p = 0.99$
Age at ART initiation, y, mean (SD)	6.1 (3.2)	5.1 (3.3)	$t = -3.04$, $p = 0.003$

SD, standard deviation; TB, tuberculosis; ART, antiretroviral therapy

Supplementary Table 2: Factors associated with RV abnormalities

Variable	RV abnormalities		
	Prevalence n/N (%)	Unadjusted OR (95% CI)	P-value
Sex			
Female	9/94 (9)	1	
Male	6/103 (5)	0.58 (0.20- 1.71)	0.33
Age			
6–10 years	6/91 (7)	1	
11–16 years	9/106 (8)	1.31 (0.45- 3.84)	0.50
Age at ART initiation			
0–5 years	6/93 (6)	0.77 (0.25–2.38)	0.65
6–10 years	7/85 (8)	1	
11–16 years	2/17 (12)	1.49 (0.28–7.86)	0.64
Duration on ART			
≤ 2 years	5/55 (9)	1	
> 2 years	10/142 (7)	0.80 (0.28- 2.30)	0.6
CD4 count			
>200 cell/ μ l	14/187 (7)	1	
≤200 cell/ μ l	0	-	-
Viral load			
≤400 copies/ml	15/152 (10)	1	
>400 copies/ml	0	-	-
Nevirapine *			
No	9/98 (9)	1	
Yes	6/99 (6)	0.64 (0.22–1.87)	0.41

Zidovudine*			
No	8/95 (8)	1	
Yes	7/102 (7)	0.80 (0.28–2.30)	0.68
Cardiac symptoms†			
No	9/119 (8)	1	
Yes	6/78 (8)	1.02 (0.35–2.98)	0.97
Hypertension			
No	8/92 (9)	1	
Yes	7/103 (7)	0.77 (0.27–2.20)	0.62
Chronic lung disease			
No	10/121 (8)	1	
Yes	5/76 (7)	0.78 (0.26–2.38)	0.67

*ART, antiretroviral therapy; RV, right ventricular; * Antiretroviral drugs; † cardiac signs and symptoms included hypoxia, chest pains, tachypnoea, and ankle swelling*